Repligen (RGEN) Tops Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
May 4, 2021 7:30 AM EDTReported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69%Growth driven by combination of COVID-related demand, base business strength and acquisition revenue
WALTHAM, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Â Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2021. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2021, and access information for todays webcast and... More
